Otsuka Pharmaceutical has launched its OralTag abdominal CT contrast agent in the U.S.
Developed by Otsuka subsidiary Interpharma Praha, OralTag is a dissolvable powder form of iohexol. The U.S. Food and Drug Administration (FDA) approved OralTag in March 2015 for use as a radiographic contrast agent for opacifying the gastrointestinal tract during CT scanning of the abdomen and pelvis.
Otsuka noted that OralTag is not indicated for diagnostic examination of the gastrointestinal tract and is contraindicated in patients with a known hypersensitivity to iodinated contrast agents, including iohexol.
OralTag will be marketed by imaging accessories firm Beekley Medical and commercially available from Beekley subsidiary WMB Enterprises.
